Phase I, Open, Sequential Vaccination Study on Safety and Tolerability of Two Different Doses of a Recombinant MVA HIV Polytope Vaccine (MVA-mBN32) in HIV-Negative 18-50 Year Old Healthy Volunteers

Trial Profile

Phase I, Open, Sequential Vaccination Study on Safety and Tolerability of Two Different Doses of a Recombinant MVA HIV Polytope Vaccine (MVA-mBN32) in HIV-Negative 18-50 Year Old Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Feb 2015

At a glance

  • Drugs EP 1232 (Primary)
  • Indications HIV-1 infections; Various toxicities
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Bavarian Nordic
  • Most Recent Events

    • 28 Dec 2007 Status changed from in progress to completed.
    • 06 Nov 2007 Bavarian Nordic has announced that enrolment is complete and all vaccinations have been administered. The first immunogenicity data will be available before the end of 2007.
    • 16 Jul 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top